Hector M. Maldonado

Influenza viruses (INF-A and INF-B) are responsible for a well-known infectious disease that affects humans.  Current treatment options are limited and emergence of resistant strains highlight the need for development of new and effective therapeutic treatments.  We perform In Silico drug discovery targeting protein-protein interaction.  It is anticipated that this effort will result in the identification of highly potent, selective and safe compounds with demonstrated broad-spectrum antiviral activity against a number of Influenza virus strains.  It is the ultimate goal of this effort to provide a therapeutic alternative that can be used for effective treatment and/or prevention of INF infections.